1. Patient-reported outcome assessment of inflammatory arthritis patient experience with intravenously administered biologic therapy
- Author
-
Raphael J. DeHoratius, Wesley A. Kafka, Kezhen L. Tang, Joanne Sagliani, Norman B. Gaylis, Shawn Black, and D. Parenti
- Subjects
medicine.medical_specialty ,patient satisfaction ,Single visit ,Inflammatory arthritis ,Medicine (miscellaneous) ,Arthritis ,03 medical and health sciences ,0302 clinical medicine ,Patient questionnaire ,Patient satisfaction ,Internal medicine ,Patient experience ,medicine ,030212 general & internal medicine ,biologic therapy ,Pharmacology, Toxicology and Pharmaceutics (miscellaneous) ,Original Research ,030203 arthritis & rheumatology ,business.industry ,Health Policy ,medicine.disease ,arthritis ,Patient Preference and Adherence ,intravenous ,Physical therapy ,Disease characteristics ,Patient-reported outcome ,business ,Social Sciences (miscellaneous) - Abstract
Norman B Gaylis,1 Joanne Sagliani,1 Shawn Black,2 Kezhen L Tang,3 Raphael DeHoratius,2,4 Wesley A Kafka,2 Dennis Parenti2 1Arthritis & Rheumatic Disease Specialties, Aventura, FL, USA; 2Medical Affairs Rheumatology, Janssen Scientific Affairs, LLC, Horsham, PA, USA; 3Quantitative Sciences, Janssen Research & Development, LLC, Spring House, PA, USA; 4Department of Medicine and Pharmacology, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA, USA Objective: To evaluate patient perspectives regarding utilization of intravenous (IV) therapy for inflammatory arthritis (IA).Methods: This was a single-center, noninterventional, patient questionnaire-based study of adult IA patients currently receiving IV biologics. At a single visit, patients completed the questionnaire comprising 30 questions centered on their experience receiving an intravenously administered therapy to treat their IA. The questionnaire included questions on patient demographics, disease characteristics, and previous biologic treatment for IA (subcutaneous [SC] and IV). Patients rated their level of agreement with statements regarding satisfaction with current IV biologic therapy and potential advantages and disadvantages of IV biologic therapy using a 5-point Likert scale (1=strongly disagree, 5=strongly agree).Results: One hundred patients were enrolled and completed the survey; 66% were female and the mean age was 58 years. Before IV treatment, 97% of patients received information regarding therapy options. Ninety patients ranked their satisfaction with current IV therapy as 4 or 5. The proportion of patients with an “extremely favorable” perception of IV therapy increased from 33% to 71% following initiation of their current medication. Thirty-one patients had previously received SC therapies to treat their IA.Conclusion: These results demonstrated an overall favorable perception of IV therapy among this patient population. Patients previously treated with SC therapy also had a positive shift in the perception of IV therapy after initiating IV therapy. Patients’ perception and preference for treatment options should be highly considered by the treating physician during or as part of a shared decision-making process. Keywords: intravenous, patient satisfaction, arthritis, biologic therapy
- Published
- 2017